Cannabidiol (Epidiolex) vs Cannabidiol (Kanbis)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Dravet Syndrome

Shared mechanism: cannabinoid · full Dravet Syndrome pipeline

Cannabidiol (Epidiolex)

Marketed by Jazz Pharmaceuticals and partners

Approved in Dravet Syndromesmall molecule
Reliable signal

NCT02091375 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 120 participants (61 receiving cannabidiol and 59 placebo) using convulsive seizure frequency as its primary clinical endpoint. The primary comparison was met: median seizure frequency fell 38.94% with cannabidiol versus 13.29% with placebo, with p=0.0123.

Next expected readout: August 2027 · NCT05044819 (registry estimate)

Reported efficacy

Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) (met)

Result source: NCT02091375

Cannabidiol (Kanbis)

Marketed by Laboratorio Elea Phoenix S.A.

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Dravet Syndrome

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Cannabidiol (Kanbis): no structured comparison results are available for Dravet Syndrome.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cannabidiol (Epidiolex)

Convulsive Seizure Frequency -38.94% (n=61) vs -13.29% (n=59) placebo @ 14.1wk20 mg/kg/day
percent change · % of baseline
NCT02091375 · Phase 3
Convulsive Seizure 50 % 42.6% (n=61) vs 27.1% (n=59) placebo @ 14.1wk20 mg/kg/day
responder rate · % of participants
NCT02091375 · Phase 3 · converted to % from 26 Participants as posted
show 2 more results
49.3% (n=67) vs 26.2% (n=65) placebo @ 14.1wk*20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
43.9% (n=66) vs 26.2% (n=65) placebo @ 14.1wk*10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
Non-Convulsive Seizure Frequency -40.16% (n=37) vs -34.69% (n=41) placebo @ 14.1wk20 mg/kg/day
percent change · % of baseline
NCT02091375 · Phase 3
Rescue Medication Use 59% (n=61) vs 69.5% (n=59) placebo @ 14.1wk20 mg/kg/day
event count · % of participants
NCT02091375 · Phase 3 · converted to % from 36 Participants as posted
Sleep Disturbance NRS -0.7 vs -0.3 placebo score @ 14.1wk20 mg/kg/day
absolute change · score
NCT02091375 · Phase 3
ESS 0.82 vs -0.69 placebo score @ 14.1wk20 mg/kg/day
absolute change · score
NCT02091375 · Phase 3
Convulsive Seizure Frequency -52.9% (n=315) @ 60wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
show 4 more results
-64.3% (n=315) @ 108wk
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
-69.4% (n=315) @ 156wk
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
-72.3% (n=315) @ 216wk
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
-55.6% (n=315) @ 264wk
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
Convulsive Seizure Frequency -40% (n=315)
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Last 12 weeks
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
Available safety results

Cannabidiol (Epidiolex)

Dropout rate
14.8%20 mg/kg/day
NCT02091375 · Phase 3
show 7 more results
46%Dravet Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
33.6%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
9%20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
4.5%10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
11.1%20 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
12.5%10 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
0%5 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
13.1%20 mg/kg/day
NCT02091375 · Phase 3
show 7 more results
8.3%Dravet Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
10.4%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
7.5%20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
0%10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
0%20 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
12.5%10 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
0%5 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
Serious AEs
16.4%20 mg/kg/day
NCT02091375 · Phase 3
show 7 more results
42.2%Dravet Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
42.9%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
24.6%20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
20.3%10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
11.1%20 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
25%10 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
10%5 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
20 mg/kg/day
diarrhoea 31.1% (placebo 10.2%)
somnolence 31.1% (placebo 10.2%)
decreased appetite 26.2% (placebo 5.1%)
NCT02091375 · Phase 3
show 7 more results
diarrhoea 42.2%
pyrexia 37.1%
decreased appetite 31.4%
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
diarrhoea 37.7%
pyrexia 33.6%
convulsion 32.8%
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
20 mg/kg/Day
decreased appetite 27.5% (placebo 16.9%)
diarrhoea 26.1% (placebo 12.3%)
somnolence 23.2% (placebo 13.8%)
NCT02224703 · Phase 3 · registry result, not featured evidence
10 mg/kg/Day
pyrexia 23.4% (placebo 16.9%)
somnolence 21.9% (placebo 13.8%)
diarrhoea 17.2% (placebo 12.3%)
NCT02224703 · Phase 3 · registry result, not featured evidence
20 mg/kg/day
decreased appetite 44.4% (placebo 0%)
abdominal pain upper 22.2% (placebo 0%)
sedation 22.2% (placebo 0%)
NCT02091206 · Phase 2 · registry result, not featured evidence
10 mg/kg/day
somnolence 37.5% (placebo 14.3%)
coordination abnormal 12.5% (placebo 0%)
decreased appetite 12.5% (placebo 0%)
NCT02091206 · Phase 2 · registry result, not featured evidence
5 mg/kg/day
abnormal behaviour 30% (placebo 0%)
pyrexia 30% (placebo 0%)
ataxia 20% (placebo 0%)
NCT02091206 · Phase 2 · registry result, not featured evidence

Lennox-Gastaut Syndrome

Shared mechanism: cannabinoid · full Lennox-Gastaut Syndrome pipeline

Cannabidiol (Epidiolex)

Marketed by Jazz Pharmaceuticals and partners

Approved in Lennox-Gastaut Syndromesmall molecule
Partial signal

NCT02224690 · Phase 3 · completed

Participants were randomized to cannabidiol (86) or matching placebo (85), with participants, caregivers, investigators, and outcome assessors blinded. The primary seizure-frequency endpoint was statistically met in favor of cannabidiol (p=0.0135), but no primary-endpoint power calculation is reported in the available sources, so the evidence is graded as moderate rather than strong.

Next expected readout: August 2027 · NCT05044819 (registry estimate)

Reported efficacy

Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -41.86 percentage change (IQR -72.4 to -1.3) | GWP42003-P 10 mg/kg/Day Dose -37.16 percentage change (IQR -63.8 to -5.6) vs Placebo -17.17 percentage change (IQR -37.1 to 0.9) (met)

Result source: NCT02224560

Cannabidiol (Kanbis)

Marketed by Laboratorio Elea Phoenix S.A.

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Lennox-Gastaut Syndrome

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Cannabidiol (Kanbis): no structured comparison results are available for Lennox-Gastaut Syndrome.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cannabidiol (Epidiolex)

Drop Seizure Frequency -43.9% (n=86) vs -21.8% (n=85) placebo @ 14.14wk20 mg/kg/day
percent change · % of baseline
NCT02224690 · Phase 3
show 2 more results
-41.86% (n=76) vs -17.17% (n=76) placebo @ 14.14wk20 mg/kg/day
NCT02224560 · Phase 3
-37.16% (n=73) vs -17.17% (n=76) placebo @ 14.14wk10 mg/kg/day
NCT02224560 · Phase 3
Drop Seizure 44.2% (n=86) vs 23.5% (n=85) placebo @ 14.14wk20 mg/kg/day
responder rate · % of participants
NCT02224690 · Phase 3 · converted to % from 38 Participants as posted
show 2 more results
39.5% (n=76) vs 14.5% (n=76) placebo @ 14.14wk*20 mg/kg/day
NCT02224560 · Phase 3 · converted to % from 30 Participants as posted
35.6% (n=73) vs 14.5% (n=76) placebo @ 14.14wk*10 mg/kg/day
NCT02224560 · Phase 3 · converted to % from 26 Participants as posted
Seizure Frequency -41.24% (n=86) vs -13.7% (n=85) placebo @ 14.14wk20 mg/kg/day
percent change · % of baseline
NCT02224690 · Phase 3
show 2 more results
-38.4% (n=76) vs -18.47% (n=76) placebo @ 14.14wk20 mg/kg/day
NCT02224560 · Phase 3
-36.44% (n=73) vs -18.47% (n=76) placebo @ 14.14wk10 mg/kg/day
NCT02224560 · Phase 3
Drop Seizure Frequency -59.4% (n=366) @ 60wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
show 3 more results
-69.4% (n=366) @ 108wk
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
-70.8% (n=366) @ 156wk
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
-68.7% (n=366) @ 216wk
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
Drop Seizure Frequency -59.4% (n=366)
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Last 12 weeks
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
Available safety results

Cannabidiol (Epidiolex)

Dropout rate
16.3%20 mg/kg/day
NCT02224690 · Phase 3
show 4 more results
11.8%20 mg/kg/day
NCT02224560 · Phase 3
2.7%10 mg/kg/day
NCT02224560 · Phase 3
46%Dravet Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
33.6%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
9.3%20 mg/kg/day
NCT02224690 · Phase 3
show 4 more results
5.3%20 mg/kg/day
NCT02224560 · Phase 3
1.4%10 mg/kg/day
NCT02224560 · Phase 3
8.3%Dravet Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
10.4%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
Serious AEs
23.3%20 mg/kg/day
NCT02224690 · Phase 3
show 4 more results
—20 mg/kg/day
NCT02224560 · Phase 3
—10 mg/kg/day
NCT02224560 · Phase 3
42.2%Dravet Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
42.9%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
20 mg/kg/day
diarrhoea 18.6% (placebo 8.2%)
somnolence 14% (placebo 9.4%)
decreased appetite 12.8% (placebo 2.4%)
NCT02224690 · Phase 3
show 2 more results
diarrhoea 42.2%
pyrexia 37.1%
decreased appetite 31.4%
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy
diarrhoea 37.7%
pyrexia 33.6%
convulsion 32.8%
NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cannabidiol (Epidiolex)'s landscape · Cannabidiol (Kanbis)'s landscape